o in Royalty Pharma's Proposal;
Prothena Corporation plc;
Securities and Exchange Commission;
Alkermes plc, Allergan, Inc., Cubist Pharmaceuticals, Inc., Endo Health Solutions
Inc., Forest Laboratories, Inc., Jazz Pharmaceuticals plc, The Medicines Company,
Salix Pharmaceuticals, Ltd., Shire plc, Valeant Pharmaceuticals International, Inc. and Warner
"Tysabri Conference Call"
the February 6, 2013 conference call following the announcement of the Tysabri Transaction;
the consideration of US$3.249 billion payable by Biogen to Elan Group upon the completion of
the Tysabri Transaction;
the royalty on Tysabri payable by Biogen to members of the Elan Group following the completion
of the Tysabri Transaction;
the transaction between Elan and Biogen in relation to the restructuring of Elan's Tysabri collaboration with Biogen which was announced by Elan on February 6, 2013; and
Valeant Pharmaceuticals International, Inc.
APPENDIX II: Chronology of EventsThe following chronology of recent events is provided as further background to the Proposal.
September 2011: Sale of Elan Drug Technologies (EDT) to Alkermes plc.
Summer 2012: Post-bapineuzumab clinical failure and announcement of spin-off of Prothena, Royalty Pharma developed an interest in Elan and Tysabri.
October to December 2012: Royalty Pharma had in-person meeting and several subsequent communications with Elan discussing ways in which Elan and Royalty Pharma might be able to work together, including Royalty Pharma's interest in potentially acquiring Elan.
6 February 2013: Biogen and Elan announced Tysabri Transact
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Related biology technology :1
. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million2
. Cowen Healthcare Royalty Partners Raises $1 Billion3
. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology4
. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz5
. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California6
. AVANIR Pharmaceuticals To participate in two conferences in March7
. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says8
. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections9
. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies10
. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 201311
. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks